ABOT Stock Overview
Manufactures, imports, and markets generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products in Pakistan, Afghanistan, Sri Lanka, Bangladesh, and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abbott Laboratories (Pakistan) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨1,181.99 |
| 52 Week High | PK₨1,299.00 |
| 52 Week Low | PK₨399.99 |
| Beta | 0.61 |
| 1 Month Change | 12.76% |
| 3 Month Change | 51.49% |
| 1 Year Change | 159.78% |
| 3 Year Change | 57.25% |
| 5 Year Change | 163.57% |
| Change since IPO | 3,029.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABOT | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -0.0008% | -5.8% | -6.3% |
| 1Y | 159.8% | 152.4% | 48.4% |
Return vs Industry: ABOT exceeded the PK Pharmaceuticals industry which returned 152.4% over the past year.
Return vs Market: ABOT exceeded the PK Market which returned 48.4% over the past year.
Price Volatility
| ABOT volatility | |
|---|---|
| ABOT Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in PK Market | 10.0% |
| 10% least volatile stocks in PK Market | 4.8% |
Stable Share Price: ABOT has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: ABOT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 1,430 | n/a | www.pk.abbott |
Abbott Laboratories (Pakistan) Limited manufactures, imports, and markets generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products in Pakistan, Afghanistan, Sri Lanka, Bangladesh, and Switzerland. It operates through Pharmaceutical, Nutritional, Diagnostics, and Others segments. The company offers portfolio of products in various therapeutic areas, including women’s and men’s health, gastroenterology, central nervous system, pediatrics, vitamins, cardiometabolic and metabolic, pain and fever, respiratory, and hospital care.
Abbott Laboratories (Pakistan) Limited Fundamentals Summary
| ABOT fundamental statistics | |
|---|---|
| Market cap | PK₨116.49b |
| Earnings (TTM) | PK₨5.00b |
| Revenue (TTM) | PK₨63.81b |
23.1x
P/E Ratio1.8x
P/S RatioIs ABOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABOT income statement (TTM) | |
|---|---|
| Revenue | PK₨63.81b |
| Cost of Revenue | PK₨46.27b |
| Gross Profit | PK₨17.55b |
| Other Expenses | PK₨12.54b |
| Earnings | PK₨5.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 51.11 |
| Gross Margin | 27.50% |
| Net Profit Margin | 7.84% |
| Debt/Equity Ratio | 0% |
How did ABOT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abbott Laboratories (Pakistan) Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvind Anand | Fortune Securities Limited |
| Naima Ali | Shajar Capital Pakistan (Private) Limited |